JPH0559892B2 - - Google Patents
Info
- Publication number
- JPH0559892B2 JPH0559892B2 JP25128684A JP25128684A JPH0559892B2 JP H0559892 B2 JPH0559892 B2 JP H0559892B2 JP 25128684 A JP25128684 A JP 25128684A JP 25128684 A JP25128684 A JP 25128684A JP H0559892 B2 JPH0559892 B2 JP H0559892B2
- Authority
- JP
- Japan
- Prior art keywords
- substance
- weight
- antitumor agent
- active ingredient
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 239000000126 substance Substances 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 6
- HNNIWKQLJSNAEQ-UHFFFAOYSA-N Benzydamine hydrochloride Chemical compound Cl.C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 HNNIWKQLJSNAEQ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229960001689 benzydamine hydrochloride Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000006268 Sarcoma 180 Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25128684A JPS61129124A (ja) | 1984-11-28 | 1984-11-28 | 抗腫瘍剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25128684A JPS61129124A (ja) | 1984-11-28 | 1984-11-28 | 抗腫瘍剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61129124A JPS61129124A (ja) | 1986-06-17 |
| JPH0559892B2 true JPH0559892B2 (ru) | 1993-09-01 |
Family
ID=17220542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP25128684A Granted JPS61129124A (ja) | 1984-11-28 | 1984-11-28 | 抗腫瘍剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61129124A (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| GB2516436A (en) * | 2013-07-20 | 2015-01-28 | Pornthip Lattmann | Benzydamine, an anti-neoplastic agent, acting as cholecystokinin antagonist Gl and brain cancers |
| CN107873024A (zh) * | 2015-02-09 | 2018-04-03 | 塞尔利克斯生物私人有限公司 | 用于治疗粘膜炎的组合物和方法 |
-
1984
- 1984-11-28 JP JP25128684A patent/JPS61129124A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61129124A (ja) | 1986-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1583661A (en) | Tumour antidote | |
| JPH0430924B2 (ru) | ||
| JP2826379B2 (ja) | チアゾリジン誘導体を有効成分とする肥満性高血圧症治療剤 | |
| US4879276A (en) | Method for reducing serum uric acid levels | |
| JPH0559892B2 (ru) | ||
| JPH0548207B2 (ru) | ||
| JPH0528690B2 (ru) | ||
| JPH07277964A (ja) | 抗腫瘍剤 | |
| EP0005074A1 (en) | A material and composition for reducing blood pressure | |
| JPH0324446B2 (ru) | ||
| JPH03502802A (ja) | 抗嘔吐性エルゴリン誘導体 | |
| JPH0442368B2 (ru) | ||
| JPH0344049B2 (ru) | ||
| JPS61129128A (ja) | 抗腫瘍剤 | |
| JPS61129121A (ja) | 抗腫瘍剤 | |
| JPH0329766B2 (ru) | ||
| JPH0425933B2 (ru) | ||
| JPH0528687B2 (ru) | ||
| JPH0649648B2 (ja) | 酢酸誘導体を含有する抗腫瘍剤 | |
| US20040142882A1 (en) | Use of glycyrrhizin and its derivatives as RANTES inducers | |
| JPH0528704B2 (ru) | ||
| JP2843944B2 (ja) | 利胆剤 | |
| JPH0735329B2 (ja) | 酢酸誘導体を含有する抗腫瘍剤 | |
| EP1038533A1 (en) | Medicinal compositions for treating immunodeficiency diseases | |
| JPH072634B2 (ja) | 酢酸誘導体を含有する抗腫瘍剤 |